You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNadolol
Accession NumberDB01203  (APRD00301)
TypeSmall Molecule
GroupsApproved
DescriptionA non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]
Structure
Thumb
Synonyms
Corgard
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CorgardTablet80 mg/1OralUs World Meds, Llc2016-04-01Not applicableUs
CorgardTablet40 mg/1OralPfizer Laboratories Div Pfizer Inc1979-12-10Not applicableUs
CorgardTablet20 mg/1OralUs World Meds, Llc2016-04-01Not applicableUs
CorgardTablet80 mg/1OralPfizer Laboratories Div Pfizer Inc1979-12-10Not applicableUs
CorgardTablet40 mg/1OralUs World Meds, Llc2016-04-01Not applicableUs
CorgardTablet20 mg/1OralPfizer Laboratories Div Pfizer Inc1979-12-10Not applicableUs
Corgard Tab 160mgTablet160 mgOralBristol Myers Squibb Canada1981-12-312004-10-29Canada
Corgard Tab 40mgTablet40 mgOralBristol Myers Squibb Canada1984-12-312006-05-29Canada
Corgard Tab 80mgTablet80 mgOralBristol Myers Squibb Canada1979-12-312006-10-25Canada
NadololTablet20 mg/1OralGreenstone LLC2014-04-28Not applicableUs
NadololTablet80 mgOralAa Pharma Inc1988-12-31Not applicableCanada
NadololTablet40 mg/1OralGreenstone LLC2014-04-28Not applicableUs
NadololTablet160 mgOralAa Pharma Inc1988-12-31Not applicableCanada
NadololTablet80 mg/1OralGreenstone LLC2014-04-28Not applicableUs
NadololTablet40 mgOralAa Pharma Inc1988-12-31Not applicableCanada
Nadolol-160 Tab 160mgTablet160 mgOralPro Doc Limitee1989-12-312014-07-24Canada
Nadolol-40 Tab 40mgTablet40 mgOralPro Doc Limitee1989-12-312015-07-10Canada
Nadolol-80 Tab 80mgTablet80 mgOralPro Doc Limitee1989-12-312015-07-10Canada
Ratio-nadolol Tab 160mgTablet160 mgOralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Ratio-nadolol Tab 40mgTablet40 mgOralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Ratio-nadolol Tab 80mgTablet80 mgOralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Teva-nadololTablet40 mgOralTeva Canada Limited1994-12-31Not applicableCanada
Teva-nadololTablet80 mgOralTeva Canada Limited1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NadololTablet40 mg/1OralDispensing Solutions, Inc.2008-10-01Not applicableUs
NadololTablet40 mg/1OralSandoz Inc2008-10-01Not applicableUs
NadololTablet40 mg/1OralMylan Institutional Inc.1994-07-12Not applicableUs
NadololTablet40 mg/1OralCipla USA Inc.2016-02-23Not applicableUs
NadololTablet20 mg/1OralTeva Pharmaceuticals USA Inc2008-11-03Not applicableUs
NadololTablet20 mg/1OralCamber, Pharmaceuticals Inc2016-01-27Not applicableUs
NadololTablet20 mg/1OralRebel Distributors Corp2008-10-01Not applicableUs
NadololTablet20 mg/1OralAmerican Health Packaging2014-04-14Not applicableUs
NadololTablet20 mg/1OralBlue Point Laboratories2014-02-05Not applicableUs
NadololTablet80 mg/1OralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs
NadololTablet80 mg/1OralSandoz Inc2008-10-01Not applicableUs
NadololTablet20 mg/1OralAvera Mc Kennan Hospital2015-08-18Not applicableUs
NadololTablet40 mg/1OralTeva Pharmaceuticals USA Inc2008-11-03Not applicableUs
NadololTablet20 mg/1OralREMEDYREPACK INC.2013-02-22Not applicableUs
NadololTablet80 mg/1OralCipla USA Inc.2016-02-23Not applicableUs
NadololTablet40 mg/1OralCamber, Pharmaceuticals Inc2016-01-27Not applicableUs
NadololTablet20 mg/1OralRebel Distributors Corp2011-01-18Not applicableUs
NadololTablet40 mg/1OralAmerican Health Packaging2014-04-14Not applicableUs
NadololTablet40 mg/1OralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs
NadololTablet40 mg/1OralRebel Distributors Corp2008-10-01Not applicableUs
NadololTablet20 mg/1OralAmerican Health Packaging2014-04-012015-12-31Us
NadololTablet80 mg/1OralBlue Point Laboratories2014-02-05Not applicableUs
NadololTablet80 mg/1OralTeva Pharmaceuticals USA Inc2008-11-03Not applicableUs
NadololTablet40 mg/1OralPhysicians Total Care, Inc.2010-01-14Not applicableUs
NadololTablet80 mg/1OralCamber, Pharmaceuticals Inc2016-01-27Not applicableUs
NadololTablet40 mg/1OralRebel Distributors Corp2011-01-18Not applicableUs
NadololTablet80 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
NadololTablet20 mg/1OralSandoz Inc2008-10-01Not applicableUs
NadololTablet80 mg/1OralRebel Distributors Corp2008-10-01Not applicableUs
NadololTablet40 mg/1OralAmerican Health Packaging2014-04-012015-12-31Us
NadololTablet40 mg/1OralBlue Point Laboratories2014-02-05Not applicableUs
NadololTablet20 mg/1OralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs
NadololTablet20 mg/1OralPhysicians Total Care, Inc.2005-05-16Not applicableUs
NadololTablet20 mg/1OralCipla USA Inc.2016-02-23Not applicableUs
NadololTablet20 mg/1OralMylan Institutional Inc.1994-07-12Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnabetNot Available
SolgolNot Available
Brand mixtures
NameLabellerIngredients
CorzidePfizer Laboratories Div Pfizer Inc
Corzide Tab W Nadolol 40mgSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Corzide Tab W Nadolol 80mgSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Nadolol and BendroflumethiazideImpax Generics
SaltsNot Available
Categories
UNIIFEN504330V
CAS number42200-33-9
WeightAverage: 309.4006
Monoisotopic: 309.194008357
Chemical FormulaC17H27NO4
InChI KeyVWPOSFSPZNDTMJ-UCWKZMIHSA-N
InChI
InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
IUPAC Name
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
SMILES
CC(C)(C)NCC(O)COC1=CC=CC2=C1C[[email protected]](O)[[email protected]](O)C2
Pharmacology
IndicationUsed in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension.
Structured Indications
PharmacodynamicsNadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Mechanism of actionLike other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
antagonist
HumanP07550 details
Related Articles
AbsorptionAbsorption of nadolol after oral dosing is variable, averaging about 30 percent.
Volume of distributionNot Available
Protein binding30%
Metabolism

Not metabolized by the liver and excreted unchanged primarily by the kidneys.

Route of eliminationUnlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys. Nadolol is excreted predominantly in the urine.
Half life14-24 hours
ClearanceNot Available
ToxicityOral, mouse: LD50 = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nadolol Action PathwayDrug actionSMP00303
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Nadolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nadolol.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nadolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Nadolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Nadolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Nadolol.Approved
AcetaminophenThe serum concentration of Nadolol can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nadolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideNadolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Nadolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Nadolol is combined with Acetylcholine.Approved
AcetyldigitoxinNadolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Nadolol.Approved
AfatinibThe serum concentration of Nadolol can be increased when it is combined with Afatinib.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Nadolol.Experimental, Investigational
AlbendazoleThe serum concentration of Nadolol can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.Approved
AldosteroneThe serum concentration of Nadolol can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Nadolol can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Nadolol can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Nadolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Nadolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Nadolol is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Nadolol.Approved, Withdrawn
AmantadineThe serum concentration of Nadolol can be increased when it is combined with Amantadine.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Nadolol.Approved
AmbrisentanNadolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateNadolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineNadolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nadolol.Approved
Aminohippuric acidThe serum concentration of Nadolol can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineNadolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Nadolol.Approved, Investigational
AmitriptylineThe serum concentration of Nadolol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nadolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nadolol.Approved, Illicit
AmodiaquineThe metabolism of Nadolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Nadolol is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Nadolol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Nadolol can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Nadolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Nadolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Nadolol.Approved
AnvirzelNadolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nadolol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Nadolol.Approved, Investigational
ArbutamineNadolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Nadolol is combined with Arecoline.Experimental
ArformoterolNadolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nadolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Nadolol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Nadolol is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Nadolol can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Nadolol can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nadolol.Approved
AtorvastatinThe serum concentration of Nadolol can be increased when it is combined with Atorvastatin.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Nadolol.Withdrawn
AzelastineThe serum concentration of Nadolol can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nadolol is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Nadolol can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Nadolol.Approved, Investigational
BambuterolNadolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Nadolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Nadolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Nadolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nadolol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nadolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nadolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Nadolol.Withdrawn
BenzocaineThe serum concentration of Nadolol can be increased when it is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Illicit
BepridilThe serum concentration of Nadolol can be increased when it is combined with Bepridil.Approved, Withdrawn
BeractantNadolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nadolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Nadolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Nadolol.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Nadolol.Approved, Investigational
BiperidenThe serum concentration of Nadolol can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nadolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Nadolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Nadolol is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Nadolol.Approved, Investigational
BosutinibThe serum concentration of Nadolol can be increased when it is combined with Bosutinib.Approved
BretyliumBretylium may increase the bradycardic activities of Nadolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nadolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Nadolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Nadolol.Investigational
BucindololNadolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nadolol.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Nadolol.Approved, Investigational
BupranololNadolol may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Nadolol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Nadolol can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Nadolol can be increased when it is combined with Cabazitaxel.Approved
CabergolineNadolol may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe serum concentration of Nadolol can be increased when it is combined with Caffeine.Approved
CalfactantNadolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nadolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nadolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Nadolol.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nadolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Nadolol is combined with Carbachol.Approved
CarbamazepineThe serum concentration of Nadolol can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Nadolol is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nadolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nadolol.Approved
CarvedilolNadolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Nadolol can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may decrease the antihypertensive activities of Nadolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Nadolol.Approved, Investigational
CeliprololNadolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibNadolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Nadolol is combined with Cevimeline.Approved
ChloroquineThe serum concentration of Nadolol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nadolol.Approved, Vet Approved
ChlorpromazineThe serum concentration of Nadolol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Nadolol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Nadolol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nadolol.Approved
CholesterolThe serum concentration of Nadolol can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Nadolol can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Nadolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Nadolol is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Nadolol can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Nadolol can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Nadolol can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Nadolol can be increased when it is combined with Clarithromycin.Approved
ClenbuterolNadolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nadolol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Nadolol is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Nadolol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Nadolol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Nadolol.Approved
ClotrimazoleThe serum concentration of Nadolol can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Nadolol is combined with Clozapine.Approved
CobicistatThe serum concentration of Nadolol can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Nadolol can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Nadolol can be increased when it is combined with Colforsin.Experimental
ConivaptanThe risk or severity of adverse effects can be increased when Nadolol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Nadolol.Vet Approved
CrizotinibThe serum concentration of Nadolol can be increased when it is combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nadolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Nadolol.Investigational
CyclophosphamideThe serum concentration of Nadolol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Nadolol can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Nadolol.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Nadolol.Investigational
DaclatasvirThe serum concentration of Nadolol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Nadolol can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Nadolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Nadolol can be increased when it is combined with Dapoxetine.Investigational
DasatinibThe serum concentration of Nadolol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Nadolol can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinNadolol may increase the hypotensive activities of Debrisoquin.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Nadolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Nadolol.Approved
DeserpidineNadolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Nadolol is combined with Desflurane.Approved
DesipramineThe serum concentration of Nadolol can be increased when it is combined with Desipramine.Approved
DeslanosideNadolol may increase the bradycardic activities of Deslanoside.Approved
DesloratadineThe serum concentration of Nadolol can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Nadolol can be increased when it is combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Nadolol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Vet Approved
DextromethorphanThe serum concentration of Nadolol can be increased when it is combined with Dextromethorphan.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nadolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Nadolol.Vet Approved
DiclofenacThe serum concentration of Nadolol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nadolol.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Nadolol.Approved
DigitoxinNadolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinThe serum concentration of Nadolol can be decreased when it is combined with Digoxin.Approved
DihydralazineNadolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nadolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nadolol is combined with Dinutuximab.Approved
DipivefrinNadolol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Nadolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Nadolol.Approved
DobutamineNadolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Nadolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nadolol.Approved
DoxazosinNadolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe serum concentration of Nadolol can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Nadolol can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Nadolol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Nadolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Nadolol.Approved
DroxidopaNadolol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetineNadolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Nadolol.Investigational
DyphyllineNadolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Nadolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Nadolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Nadolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Nadolol.Approved
EfonidipineNadolol may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Nadolol can be increased when it is combined with Elbasvir.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nadolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nadolol.Approved, Vet Approved
EnalaprilatNadolol may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Nadolol can be increased when it is combined with Enzalutamide.Approved
EphedraNadolol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Nadolol is combined with EPIBATIDINE.Experimental
EpinephrineNadolol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Nadolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nadolol.Approved
EpoprostenolNadolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nadolol.Approved
Ergoloid mesylateNadolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineNadolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
ErythromycinThe serum concentration of Nadolol can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nadolol.Approved
EstramustineThe serum concentration of Nadolol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Nadolol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Nadolol can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nadolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Nadolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Nadolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Nadolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
EtoperidoneThe serum concentration of Nadolol can be increased when it is combined with Etoperidone.Approved
EtoposideThe serum concentration of Nadolol can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Nadolol.Approved, Investigational
EtravirineThe serum concentration of Nadolol can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Nadolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Nadolol.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nadolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Nadolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Nadolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Nadolol.Approved
FenoterolNadolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylThe serum concentration of Nadolol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Nadolol.Vet Approved
FexofenadineThe serum concentration of Nadolol can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Nadolol can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Nadolol is combined with Fimasartan.Approved
FingolimodNadolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nadolol.Approved, Withdrawn
FluconazoleThe serum concentration of Nadolol can be increased when it is combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Nadolol.Vet Approved
FluoxetineThe serum concentration of Nadolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Nadolol can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Nadolol can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Nadolol can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Nadolol.Approved, Investigational
FluvoxamineThe serum concentration of Nadolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolNadolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nadolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nadolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nadolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Nadolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Nadolol.Approved
GefitinibThe serum concentration of Nadolol can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Nadolol can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Nadolol.Approved, Nutraceutical
GlibornurideNadolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideNadolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideNadolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideNadolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneNadolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideNadolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideThe serum concentration of Nadolol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Nadolol can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Nadolol can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Nadolol can be increased when it is combined with Grepafloxacin.Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Nadolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Nadolol.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Nadolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
HaloperidolThe serum concentration of Nadolol can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Nadolol is combined with Halothane.Approved, Vet Approved
HexamethoniumNadolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Nadolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Nadolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Nadolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Nadolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Nadolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Nadolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nadolol.Approved, Vet Approved
HydrocortisoneThe serum concentration of Nadolol can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nadolol.Approved
HydroxychloroquineThe metabolism of Nadolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Nadolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Nadolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Nadolol.Approved
IdelalisibThe serum concentration of Nadolol can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Nadolol.Approved, Investigational
ImatinibThe serum concentration of Nadolol can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Nadolol is combined with Imidapril.Investigational
ImipramineThe serum concentration of Nadolol can be increased when it is combined with Imipramine.Approved
IndacaterolNadolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Nadolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nadolol.Approved
IndenololNadolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Nadolol can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Nadolol can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Nadolol.Withdrawn
IndoraminNadolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkNadolol may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypotensive activities of Nadolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nadolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nadolol.Approved, Investigational
IsavuconazoniumThe serum concentration of Nadolol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nadolol.Approved
IsoetarineNadolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Nadolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Nadolol.Approved, Withdrawn
IsoprenalineNadolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nadolol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nadolol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Nadolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Nadolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nadolol.Approved
ItraconazoleThe serum concentration of Nadolol can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineNadolol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Nadolol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Nadolol can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Nadolol.Experimental
KetamineThe serum concentration of Nadolol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinNadolol may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe serum concentration of Nadolol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Nadolol.Approved
LabetalolNadolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineNadolol may increase the hypotensive activities of Lacidipine.Approved
LacosamideNadolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideNadolol may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Nadolol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Nadolol can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Nadolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Nadolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Nadolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nadolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Nadolol is combined with Levobupivacaine.Approved
LevodopaNadolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Nadolol can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Nadolol can be increased when it is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Nadolol is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Nadolol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Nadolol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Nadolol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Nadolol can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nadolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Nadolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Nadolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
LomitapideThe serum concentration of Nadolol can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Nadolol can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Nadolol can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Nadolol can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Nadolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nadolol.Approved
LovastatinThe serum concentration of Nadolol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Nadolol.Approved
LucinactantNadolol may increase the bradycardic activities of Lucinactant.Approved
LumacaftorThe serum concentration of Nadolol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Nadolol.Approved, Investigational
MacitentanNadolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Nadolol.Approved
MalathionMalathion may increase the bradycardic activities of Nadolol.Approved, Investigational
ManidipineNadolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nadolol.Approved, Investigational
MaprotilineThe serum concentration of Nadolol can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Nadolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Nadolol.Withdrawn
MebendazoleThe serum concentration of Nadolol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nadolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Nadolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Nadolol.Approved
Megestrol acetateThe serum concentration of Nadolol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Nadolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Nadolol.Approved, Vet Approved
MeprobamateThe serum concentration of Nadolol can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may decrease the antihypertensive activities of Nadolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Nadolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Nadolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Nadolol is combined with Methacholine.Approved
MethadoneThe serum concentration of Nadolol can be increased when it is combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Nadolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nadolol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nadolol.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Nadolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nadolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nadolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nadolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nadolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nadolol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Nadolol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nadolol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nadolol.Approved, Investigational
MetyrosineNadolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe serum concentration of Nadolol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Nadolol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Nadolol can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineNadolol may increase the bradycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Nadolol can be decreased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Nadolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Nadolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nadolol.Approved
MitomycinThe serum concentration of Nadolol can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Nadolol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Nadolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Nadolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nadolol.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nadolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Nadolol.Approved, Withdrawn
MorphineThe serum concentration of Nadolol can be increased when it is combined with Morphine.Approved, Investigational
MoxonidineNadolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Nadolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Nadolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nadolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Nadolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Nadolol.Approved
NaftopidilNadolol may increase the hypotensive activities of Naftopidil.Investigational
NaltrexoneThe serum concentration of Nadolol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
NaringeninThe serum concentration of Nadolol can be increased when it is combined with Naringenin.Experimental
NCX 4016NCX 4016 may decrease the antihypertensive activities of Nadolol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Nadolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nadolol can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nadolol can be decreased when it is combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Nadolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Nadolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nadolol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Nadolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nadolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Nadolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Nadolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Nadolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Nadolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Nadolol.Approved
NiguldipineNadolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nadolol can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineNadolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Nadolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nadolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nadolol.Approved
NitrazepamThe serum concentration of Nadolol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Nadolol can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nadolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Nadolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nadolol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nadolol.Approved
NorepinephrineNadolol may decrease the bronchodilatory activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Nadolol can be decreased when it is combined with Norethisterone.Approved
ObinutuzumabNadolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nadolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Nadolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nadolol.Approved, Investigational
OlodaterolNadolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Nadolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Nadolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Nadolol.Investigational
OmeprazoleThe serum concentration of Nadolol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineNadolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Nadolol.Vet Approved
OuabainNadolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Nadolol.Approved
OxprenololNadolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Nadolol.Withdrawn
P-NitrophenolThe serum concentration of Nadolol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Nadolol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
Palmitic AcidThe serum concentration of Nadolol can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Nadolol can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nadolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Nadolol.Approved
PargylinePargyline may increase the hypotensive activities of Nadolol.Approved
ParoxetineThe serum concentration of Nadolol can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideNadolol may increase the bradycardic activities of Pasireotide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nadolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Nadolol.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Nadolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nadolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Nadolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nadolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Nadolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nadolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nadolol.Withdrawn
PhenobarbitalThe serum concentration of Nadolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nadolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nadolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Nadolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
PhenylpropanolamineNadolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Nadolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Nadolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Nadolol.Approved, Investigational
PimozideThe serum concentration of Nadolol can be increased when it is combined with Pimozide.Approved
PinacidilNadolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Nadolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nadolol is combined with Pipamperone.Approved
PirbuterolNadolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Nadolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Nadolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Nadolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Nadolol.Withdrawn
Platelet Activating FactorThe serum concentration of Nadolol can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideNadolol may increase the hypotensive activities of Polythiazide.Approved
PonatinibThe serum concentration of Nadolol can be increased when it is combined with Ponatinib.Approved
Poractant alfaNadolol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Nadolol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nadolol is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Nadolol can be increased when it is combined with Pravastatin.Approved
PrazosinNadolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrednisoneThe serum concentration of Nadolol can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineThe metabolism of Nadolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Nadolol.Approved, Vet Approved
ProbenecidThe serum concentration of Nadolol can be increased when it is combined with Probenecid.Approved
ProcaterolNadolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Nadolol.Approved, Vet Approved
ProgesteroneThe serum concentration of Nadolol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Nadolol.Approved, Vet Approved
PromethazineThe serum concentration of Nadolol can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Nadolol.Approved
PropafenoneThe serum concentration of Nadolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Nadolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Nadolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nadolol.Approved, Investigational
ProtriptylineThe serum concentration of Nadolol can be increased when it is combined with Protriptyline.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Nadolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Nadolol.Approved
QuercetinThe serum concentration of Nadolol can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Nadolol is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Nadolol can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nadolol.Approved, Investigational
QuinidineThe serum concentration of Nadolol can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Nadolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nadolol.Approved
RanitidineThe serum concentration of Nadolol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Nadolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Nadolol.Approved
ReboxetineThe serum concentration of Nadolol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Nadolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nadolol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nadolol.Approved
RescinnamineNadolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Nadolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Nadolol.Experimental, Investigational
RifampicinThe serum concentration of Nadolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nadolol can be decreased when it is combined with Rifapentine.Approved
RilmenidineNadolol may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Nadolol can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Nadolol is combined with Riociguat.Approved
RisperidoneNadolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineNadolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe serum concentration of Nadolol can be decreased when it is combined with Ritonavir.Approved, Investigational
RituximabNadolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Nadolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Nadolol.Investigational, Withdrawn
RolapitantThe serum concentration of Nadolol can be increased when it is combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nadolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nadolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Nadolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nadolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nadolol.Withdrawn
SalbutamolNadolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Nadolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
SalmeterolNadolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Nadolol.Approved
SaprisartanNadolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Nadolol can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Nadolol can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Nadolol.Approved, Vet Approved
SelegilineThe serum concentration of Nadolol can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagNadolol may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Nadolol.Approved, Investigational
SertralineThe serum concentration of Nadolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nadolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nadolol.Approved, Investigational
SilodosinNadolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SimeprevirThe serum concentration of Nadolol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Nadolol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Nadolol can be decreased when it is combined with Sirolimus.Approved, Investigational
SitaxentanNadolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nadolol is combined with Sodium Nitrite.Approved
SorafenibThe serum concentration of Nadolol can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nadolol.Approved
SpiraprilNadolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nadolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Nadolol.Investigational
St. John's WortThe serum concentration of Nadolol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Nadolol can be increased when it is combined with Staurosporine.Experimental
StreptokinaseThe risk or severity of adverse effects can be increased when Nadolol is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Nadolol can be decreased when it is combined with Streptozocin.Approved
SufentanilSufentanil may increase the bradycardic activities of Nadolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Nadolol.Approved
SulfinpyrazoneThe serum concentration of Nadolol can be increased when it is combined with Sulfinpyrazone.Approved
SulindacSulindac may decrease the antihypertensive activities of Nadolol.Approved
SumatriptanThe serum concentration of Nadolol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Nadolol can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Nadolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Nadolol.Withdrawn
TacrolimusThe serum concentration of Nadolol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nadolol.Approved, Investigational
TamoxifenThe serum concentration of Nadolol can be decreased when it is combined with Tamoxifen.Approved
TamsulosinNadolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Nadolol can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nadolol.Approved, Investigational
TemocaprilNadolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Nadolol can be increased when it is combined with Temsirolimus.Approved
TenoxicamTenoxicam may decrease the antihypertensive activities of Nadolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Nadolol.Vet Approved
TerazosinNadolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineNadolol may decrease the bronchodilatory activities of Terbutaline.Approved
TerfenadineThe serum concentration of Nadolol can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Nadolol.Approved
TerlipressinNadolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Nadolol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Nadolol can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nadolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineNadolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Nadolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Nadolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Nadolol.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Nadolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Nadolol.Approved
TiboloneNadolol may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Nadolol can be increased when it is combined with Ticagrelor.Approved
TicrynafenNadolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nadolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Nadolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Nadolol.Approved, Investigational
TolazamideNadolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Nadolol.Approved, Vet Approved
TolbutamideNadolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nadolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Nadolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Nadolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Nadolol.Approved
TolvaptanThe serum concentration of Nadolol can be increased when it is combined with Tolvaptan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nadolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nadolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Nadolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nadolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Nadolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Nadolol.Approved
TrazodoneThe serum concentration of Nadolol can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Nadolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nadolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nadolol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Nadolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nadolol.Approved, Vet Approved
TrifluoperazineThe serum concentration of Nadolol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Nadolol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinNadolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nadolol.Approved
TrimethoprimThe serum concentration of Nadolol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Nadolol can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Nadolol.Approved
TroleandomycinThe serum concentration of Nadolol can be increased when it is combined with Troleandomycin.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Nadolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Nadolol.Approved, Investigational
UnoprostoneNadolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Nadolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nadolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nadolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Nadolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Nadolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nadolol.Approved
VilanterolNadolol may decrease the bronchodilatory activities of Vilanterol.Approved
VinblastineThe serum concentration of Nadolol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Nadolol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Nadolol can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineNadolol may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Nadolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Nadolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Nadolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Nadolol.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Magnesium, potassium and zinc needs increased.
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US3935267
General ReferencesNot Available
External Links
ATC CodesC07AA12C07BA12
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9788
Blood Brain Barrier-0.966
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8317
P-glycoprotein inhibitor IInhibitor0.6192
P-glycoprotein inhibitor IINon-inhibitor0.7842
Renal organic cation transporterNon-inhibitor0.8736
CYP450 2C9 substrateNon-substrate0.7934
CYP450 2D6 substrateSubstrate0.7284
CYP450 3A4 substrateNon-substrate0.5456
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8072
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8934
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.7972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Inhibitor0.5781
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral160 mg
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
TabletOral40 mg
TabletOral80 mg
Prices
Unit descriptionCostUnit
Nadolol powder94.8USD g
Corgard 160 mg tablet4.4USD tablet
Corgard 80 mg tablet4.33USD tablet
Corgard 120 mg tablet3.96USD tablet
Corgard 40 mg tablet3.11USD tablet
Corgard 20 mg tablet3.04USD tablet
Nadolol 160 mg tablet2.25USD tablet
Nadolol 80 mg tablet1.45USD tablet
Apo-Nadol 160 mg Tablet1.26USD tablet
Nadolol 40 mg tablet1.07USD tablet
Naldol 80 mg tablet1.03USD tablet
Nadolol 20 mg tablet0.92USD tablet
Apo-Nadol 80 mg Tablet0.37USD tablet
Novo-Nadolol 80 mg Tablet0.37USD tablet
Apo-Nadol 40 mg Tablet0.26USD tablet
Novo-Nadolol 40 mg Tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point124-136 °CPhysProp
water solubility8330 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.81SANGSTER (1994)
Caco2 permeability-5.41ADME Research, USCD
pKa9.67MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility2.25 mg/mLALOGPS
logP1.23ALOGPS
logP0.87ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)13.59ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area81.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85.53 m3·mol-1ChemAxon
Polarizability34.63 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
KingdomOrganic compounds
Super ClassBenzenoids
ClassTetralins
Sub ClassNot Available
Direct ParentTetralins
Alternative Parents
Substituents
  • Tetralin
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-diol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009 ]
  3. Koshiji M, Ito H, Minatoguchi S, Watanabe H, Imai Y, Kakami M, Hirakawa S: A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing. Clin Exp Pharmacol Physiol. 1992 Jul;19(7):481-8. [PubMed:1354084 ]
  4. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]
  5. Varma DR: Ligand-independent negative chronotropic responses of rat and mouse right atria to beta-adrenoceptor antagonists. Can J Physiol Pharmacol. 1999 Dec;77(12):943-9. [PubMed:10606440 ]
  6. Wheeldon NM, McDevitt DG, Lipworth BJ: Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol. 1994 Apr;37(4):363-9. [PubMed:7912539 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009 ]
  3. Ozakca I, Arioglu E, Guner S, Altan VM, Ozcelikay AT: Role of beta-3-adrenoceptor in catecholamine-induced relaxations in gastric fundus from control and diabetic rats. Pharmacology. 2007;80(4):227-38. Epub 2007 Jul 6. [PubMed:17622774 ]
  4. Liu YL, Toubro S, Astrup A, Stock MJ: Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord. 1995 Sep;19(9):678-85. [PubMed:8574280 ]
  5. Wheeldon NM, McDevitt DG, Lipworth BJ: Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol. Br J Clin Pharmacol. 1992 Apr;33(4):411-6. [PubMed:1349493 ]
  6. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23